Last reviewed · How we verify
Lotrimin Ultra®
Lotrimin Ultra contains butenafine, an allylamine antifungal that disrupts fungal cell membrane synthesis by inhibiting squalene epoxidase.
Lotrimin Ultra contains butenafine, an allylamine antifungal that disrupts fungal cell membrane synthesis by inhibiting squalene epoxidase. Used for Tinea pedis (athlete's foot), Tinea cruris (jock itch), Tinea corporis (ringworm).
At a glance
| Generic name | Lotrimin Ultra® |
|---|---|
| Sponsor | Sun Pharmaceutical Industries, Inc. |
| Drug class | Allylamine antifungal |
| Target | Squalene epoxidase |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Butenafine inhibits the enzyme squalene epoxidase, which is critical for ergosterol synthesis in fungal cell membranes. This leads to accumulation of squalene and depletion of ergosterol, destabilizing the fungal cell membrane and causing cell death. The drug is effective against dermatophytes, yeasts, and other fungi that cause superficial skin infections.
Approved indications
- Tinea pedis (athlete's foot)
- Tinea cruris (jock itch)
- Tinea corporis (ringworm)
- Tinea versicolor
Common side effects
- Contact dermatitis
- Erythema
- Burning or stinging at application site
- Pruritus
Key clinical trials
- Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis (PHASE1)
- Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lotrimin Ultra® CI brief — competitive landscape report
- Lotrimin Ultra® updates RSS · CI watch RSS
- Sun Pharmaceutical Industries, Inc. portfolio CI